Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature

British Journal of Dermatology

Volumn 178, Issue 3, 2018, Pages 650-658

  Eyraud, A ^a   Scouppe, L ^b   Barnetche, T ^b   Forcade, E ^c,d   Lazaro, E ^c,d   Duffau, P ^a,d   Richez, C ^b,d   Seneschal, J ^a,d   Truchetet, M E ^b,d  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CARBON DIOXIDE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LUNG CAPACITY; LUNG FUNCTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SAFETY PROCEDURE; SCLERODERMA; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; ADULT; AUTOTRANSPLANTATION; BLOOD; BLOOD GAS ANALYSIS; COHORT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LUNG DISEASE; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PATIENT SAFETY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; BLOOD GAS ANALYSIS; CARBON DIOXIDE; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; MALE; MIDDLE AGED; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, SYSTEMIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85044324004     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15993     Document Type: Review

References (52)

1. Mayes MD, Lacey JV, Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246–55.
2. Elhai M, Meune C, Avouac J et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51:1017–26.
3. Rebeiro P, Moore J. The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders. Intern Med J 2016; 46:17–28.
4. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68:620–8.
5. Gratwohl A, Passweg J, Gerber I et al. Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol 2001; 14:755–76.
6. Nivison-Smith I, Bradstock KF, Dodds AJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand #bib1992–2004. Biol Blood Marrow Transplant 2007; 13:905–12.
7. Delemarre EM, van den Broek T, Mijnheer G et al. Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood 2016; 127:91–101.
8. + T cells. Rheumatology (Oxford) 2011; 50:944–52.
9. Baraut J, Grigore EI, Jean-Louis F et al. Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 2014; 49:349–54.
10. van Laar JM, Farge D, Sont JK et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311:2490–8.
11. Davas EM, Peppas C, Maragou M et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18:455–61.
12. White B, Moore WC, Wigley FM et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947–54.
13. Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10:R124.
14. Verrecchia F, Laboureau J, Verola O et al. Skin involvement in scleroderma – where histological and clinical scores meet. Rheumatology (Oxford) 2007; 46:833–41.
15. Daikeler T, Kump E, Stern M et al. Autologous hematopoietic stem cell transplantation reverses skin fibrosis but does not change skin vessel density in patients with systemic sclerosis. Pathol Biol (Paris) 2015; 63:164–8.
16. Henes JC, Koetter I, Horger M et al. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology (Oxford) 2014; 53:919–22.
17. Komatsuda A, Kawabata Y, Horiuchi T et al. Successful autologous peripheral blood stem cell transplantation using thiotepa in a patient with systemic sclerosis and cardiac involvement. Tohoku J Exp Med 2006; 209:61–7.
18. Al-mashaleh M, Bak H, Moore J et al. Resolution of sclerodermatous myocarditis after autologous stem cell transplantation. Ann Rheum Dis 2006; 65:1247–8.
19. De Langhe E, Lenaerts J, Dierickx D et al. Acquired haemophilia A in a patient with systemic sclerosis treated with autologous haematopoietic stem cell transplantation. Rheumatology (Oxford) 2015; 54:196–7.
20. Szodoray P, Varoczy L, Papp G et al. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol 2012; 41:110–15.
21. Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95:284–92.
22. Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378:498–506.
23. Miniati I, Guiducci S, Conforti ML et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis 2009; 68:94–8.
24. Toledano C, Henegar C, Ilie D et al. [Cardiopulmonary function before and after cyclophosphamide treatment in severe systemic sclerosis: comparison of monthly intravenous bolus and autologous haematopoietic stem cell transplantation]. Rev Med Interne 2005; 26:444–52 (in French).
25. Rosen O, Thiel A, Massenkeil G et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2000; 2:327–36.
26. Farge D, Marolleau JP, Zohar S et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study. Br J Haematol 2002; 119:726–39.
27. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100:1602–10.
28. Nash RA, McSweeney PA, Crofford LJ et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110:1388–96.
29. Oyama Y, Barr WG, Statkute L et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007; 40:549–55.
30. Vonk MC, Marjanovic Z, van den Hoogen FHJ et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008; 67:98–104.
31. Bohgaki T, Atsumi T, Bohgaki M et al. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression. J Rheumatol 2009; 36:1240–8.
32. Launay D, Marjanovic Z, de Bazelaire C et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. J Rheumatol 2009; 36:1460–3.
33. Henes JC, Schmalzing M, Vogel W et al. Optimization of autologous stem cell transplantation for systemic sclerosis – a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012; 39:269–75.
34. Burt RK, Oliveira MC, Shah SJ et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381:1116–24.
35. Tsukamoto H, Nagafuji K, Horiuchi T et al. A phase I–II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65:508–14.
36. Moore J, Englert H, Furlong T et al. Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide. Bone Marrow Transplant 2012; 47:1486–7.
37. Hosing C, Nash R, McSweeney P et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant 2011; 17:674–81.
38. Kohno K, Nagafuji K, Tsukamoto H et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis 2009; 11:318–23.
39. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60:577–84.
40. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63:974–81.
41. Rosen O, Massenkeil G, Hiepe F et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplant 2001; 27:657–8.
42. Deligny C, Clave E, Sibon D et al. New onset of myasthenia gravis after treatment of systemic sclerosis by autologous hematopoietic stem cell transplantation: sustained autoimmunity or inadequate reset of tolerance? Hum Immunol 2010; 71:363–5.
43. Tailor IK, Akil M, Rennie I et al. Reconstitution Graves’ disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis. QJM 2012; 105:369–71.
44. Blank N, Lorenz HM. [Treatment and course of a man with systemic sclerosis before and after haematopoietic blood stem cell transplantation]. Dtsch Med Wochenschr 2013; 138:1824–7 (in German).
45. Tyndall A, Black C, Finke J et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349:254.
46. Chizzolini C, Vukicevic M, Rochat T et al. Acute natural killer cell pneumonia in a patient transplanted with autologous haematopoietic stem cells for systemic sclerosis. Rheumatology (Oxford) 2013; 52:954–6.
47. Wang J, Nash RA, Chu B et al. Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis. Bone Marrow Transplant 2009; 44:387–9.
48. Nash RA, Dansey R, Storek J et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9:583–91.
49. Cipriani P, Ruscitti P, Giacomelli R. Stem cell therapies for systemic sclerosis. Br J Haematol 2015; 168:328–37.
50. van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology (Oxford) 2015; 54:2126–33.
51. Pope JE. Connective tissue disease: reflections on the EULAR recommendations for the treatment of systemic sclerosis. Nat Rev Rheumatol 2017; 13:134–6.
52. Snowden JA, Saccardi R, Allez M et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47:770–90.